Form 8-K - Current report:
SEC Accession No. 0001683168-25-003715
Filing Date
2025-05-15
Accepted
2025-05-15 16:31:19
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 26326
2 PRESS RELEASE phio_ex9901.htm EX-99.1 39597
6 GRAPHIC image_001.jpg GRAPHIC 2326
  Complete submission text file 0001683168-25-003715.txt   253291

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20250515.xsd EX-101.SCH 3020
4 XBRL LABEL FILE phio-20250515_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE phio-20250515_pre.xml EX-101.PRE 24168
17 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 25954173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)